Survivin is a member of the "inhibitors of apoptosis" family of proteins that has been implicated in both the preservation of cell viability and the regulation of mitosis in tumor cells (Rothe et al., 1995; Roy et al., 1997; Jäättelä, 1999; Verdecia et al., 2000) . Survivin is undetectable in most normal differentiated tissues, with the exception of the normal placenta, the testes, and rapidly dividing cells such as CD34
ϩ bone marrow stem cells (Ambrosini et al., 1997; Lu et al., 1998; Tamm et al., 1998; O'Connor et al., 2000; Fukuda and Pelus, 2001) . However, survivin is highly expressed in almost all primary tumor types (Ambrosini et al., 1997; Lu et al., 1998; Tamm et al., 1998; O'Connor et al., 2000) . The high expression of survivin in tumors has been correlated with the more aggressive form of neuroblastoma (Adida et al., 1998; Islam et al., 2000) and poor survival in a range of solid and hematological malignancies, including colorectal cancer (Sarela et al., 2000) , non-small-cell lung cancer (Monzó et al., 1999) , and breast cancer (Tanaka et al., 2000) . Given its preferential expression in tumor cells, its ability to block apoptosis and to regulate cancer cell proliferation as well as its correlation with poor survival, survivin seems to be an attractive novel target for cancer therapy. Suppression of survivin renders cells sensitive to normal cell cycle regulation and induces tumor cell death (Giodini et al., 2002) . It may also make cells responsive to apoptosis induced by other chemotherapeutic agents (Yamamoto and Tanigawa, 2001) .
YM155 monobromide ( Fig. 1 ) inhibits survivin expression in tumor cells (Nakahara et al., 2007) . YM155 has been shown to exert inhibitory effects on cell growth in a variety of human tumor cell lines (Nakahara et al., 2007) . Moreover, in nude mice carrying the human hormone refractory prostate cancer, PC-3 tumors, 3-day continuous subcutaneous infusion of YM155 (3-10 mg/kg) induced massive tumor regression accompanied by suppression of intratumoral survivin (Nakahara et al., 2007) . In a phase I study conducted in the United States to investigate the safety and tolerability of YM155 7-day continuous intravenous administration every 3 weeks, three of five patients with non-Hodgkin's lymphoma showed an objective response at doses at or below the maximum tolerated dose (Tolcher et al., 2008) . Two patients with hormone refractory prostate cancer exhibited a prostate-specific antigen response (Ͼ50% reduction) and one patient with non-small-cell lung cancer exhibited a minor response (23% reduction), based on Response Evaluation Criteria in Solid Tumors (Tolcher et al., 2008) .
A previous study in nude mice bearing PC-3 xenografts reported that YM155, administered as a subcutaneous infusion reached maximum concentrations in the tumor that were approximately 20-fold higher than those in the plasma (Nakahara et al., 2007) , which suggests a specific mechanism for this high distribution. However, the concentration of YM155 in organs other than tumors has not been measured, nor has there been any detailed characterization of the uptake of YM155 into the tumor. In general, membrane transporters have been found to play important roles in the distribution of anticancer drug, and in the chemosensitivity and chemoresistance of cancer cells (Huang and Sadée, 2006 ). There have been many studies both on ATP-binding cassette transporters that cause the efflux of anticancer drugs from the cancer cells and the role of influx transporters in the uptake of anticancer drugs that are structurally related to endogenous substances and nutrients (Huang and Sadée, 2006) . However, reports on the other influx mechanisms for anticancer drugs that are not analogs of endogenous substances have been limited. Several recent studies have suggested that organic cation influx transporters may contribute to the accumulation and specificity of anticancer drugs to cancer cells [e.g., organic cation transporter 6 (OCT6/SLC22A16) for doxorubicin (Okabe et al., 2005) , OCT1 (SLC22A1) for imatinib (Thomas et al., 2004; Wang et al., 2008) , and OCT1 and OCT2 (SLC22A2) for oxaliplatin (Yonezawa et al., 2006; Zhang et al., 2006) ]. Although YM155 is in fact a substrate of human OCT1 , the role that OCT1 plays in the uptake of YM155 into cancer cells is unknown.
In this study, whole body radioluminography was performed to assess the tissue (tumor and other tissues) distribution of radioactivity after administration of [ 14 C]YM155 to nude mice bearing PC-3 xenografts. In addition, the in vitro uptake of [ 14 C]YM155 into a number of solid-and hematological tumor cell lines was characterized. The possible role of OCT1 in the uptake of YM155 into the tumor cells is also discussed.
Materials and Methods

Materials. [
14 C]YM155 monobromide (specific activity, 3.05 and 3.27 MBq/mg as monobromide; radiochemical purity not less than 98.2%) was synthesized at Sekisui Medical Co. Ltd. (Ibaraki, Japan). YM155 monobromide (molecular weight, 443.29; assay value, 100.1%) was synthesized at Astellas Pharma Inc. The dose level and concentrations were expressed as YM155, the cationic moiety of this drug substance. All other chemicals and reagents used were commercially available and of guaranteed purity.
Cell Lines. Cell lines derived from human hormone-refractory prostate adenocarcinoma (PC-3), lung cancer (Calu-6 and NCI-H358), melanoma (A375 and SK-MEL-5), and non-Hodgkin's lymphoma (RL and Ramos) were purchased from American Type Culture Collection (Manassas, VA). PC-3, Calu-6, NCI-H358, A375, SK-MEL-5, all of which have an adherent growth property, were cultured in RPMI 1640 medium (Invitrogen, Carlsbad, CA) supplemented with 10% heat-inactivated fetal bovine serum at 37°C in a humidified atmosphere of 5% CO 2 , and subcultured using trypsin EDTA. RL and Ramos, which have a nonadherent growth property, were cultured in RPMI 1640 medium supplemented with 5% heat-inactivated fetal bovine serum, at 37°C in an atmosphere of 5% CO 2 in humidified air, and subcultured by diluting the cell culture medium.
In Vivo Distribution of [ 14 C]YM155 in PC-3-Xenografted Nude Mice Using Whole Body Radioluminography. Five-week-old male nude mice (BALB/c-nu/nu) were purchased from Charles River Laboratories Japan, Inc. (Kanagawa, Japan). The mice were kept in a cage at 23 to 26°C and a relative humidity of 46 to 56%. The mice were given pellet diet (CRF-1; Oriental Yeast Co., Ltd., Tokyo, Japan) and water (well water sterilized by admixing with sodium hypochlorite; residual chlorine concentration, approximately 2 ppm) ad libitum during the acclimation and experiment periods. After acclimation for more than 5 days, PC-3 cells (3 ϫ 10 6 cells/animal) were subcutaneously injected into the right dorsum near the forelimbs of the mice and allowed to grow for 24 days to obtain a tumor volume of Ͼ250 mm 3 (length ϫ width 2 ϫ 0.5). [
14 C]YM155 was continuously infused, subcutaneously, at the rate of 3 mg/kg/day (12 MBq/kg/day) for 3 days to 2 mice using an implanted microosmotic pump (Alzet model 1003D; Durect Corporation, Cupertino, CA). YM155 induced massive tumor regression accompanied by the suppression of intratumoral survivin at the dose levels of 3 to 10 mg/kg/day (Nakahara et al., 2007) . The mice were euthanized under ether anesthesia 72 h just after infusion, after which the osmotic pump was removed. One mouse was used as the primary with the other as a backup. After the hair was removed with a pair of clippers, and the natural orifices such as the eyes, nose, mouth, ears, anus, and urogenital organs were sealed with 4% (w/v) carboxymethyl cellulose, the mice were frozen in dry ice/acetone. Afterward, the bodies were embedded in 10% (w/v) carboxymethyl cellulose and refrozen, and then 30-m-thick whole-body slices were made at Ϫ17°C using an autocryotome (PMV-450MP; Leica, Wetzlar, Germany). The slices were peeled off with adhesive tape, dried at Ϫ17°C, fixed to the imaging plate (SR-2025; Fuji Photo Film Co., Ltd., Tokyo, Japan), and exposed for a few days at room temperature. Radioluminograms were prepared by reading the radioactive images using a bioimaging analyzer (BAS-1800II; Fuji Photo Film Co., Ltd.) with a 65,536 (16 bit) gradation and 50-m resolution. The photostimulated luminescence (PSL) of each radioactive area on the radioluminograms was calculated using TINA 2.0 software (Raytest, Straubenhardt, Germany) and expressed as PSL per square millimeter. The present dosing regimen (72-h constant subcutaneous infusion at a rate of 3 mg/kg/day) for [ 14 C]YM155 is the same as that reported for nonradiolabeled YM155 (Nakahara et al., 2007) . Preliminary results showed that the pumping rate is constant and that plasma radioactivity concentrations reached the steady state within 48 h after the start of infusion (data not shown). The concentration of radioactivity in the plasma 72 h into the constant subcutaneous infusion of [ 14 C]YM155 was confirmed to be 22.3 Ϯ 5.7 ng/ml (mean Ϯ S.D. of three mice; unpublished data), which is comparable with that obtained for YM155 (approximately 20 ng/ml) in our previous study (Nakahara et al., 2007) . Because YM155 remained virtually unmetabolized in in vitro systems, such as hepatocytes, in mice and humans (Sohda et al., 2007) . The radioactivity seen in the present experiments probably reflects the concentration of unchanged YM155.
In Vitro Binding of [ 14 C]YM155 to PC-3 Xenograft Homogenate. Blank PC-3 xenografts were sampled from untreated nude mice bearing PC-3 tumors and homogenized on ice using a Potter-Elvehjem Teflon homogenizer. Phosphate buffer (0.01 M, with 0.14 M KCl, pH 7.2) was added to make final concentrations of 15 and 30% (w/w). The homogenate was spiked with [ 14 C]YM155 (100 and 1000 ng/ml) and then incubated at 37°C for 10 and 60 min, respectively. Aliquots of the homogenate samples were transferred to an ultrafiltration tube (molecular weight cut-off, 10,000; Ultracent-10, Tosoh Corporation, Tokyo, Japan) and then filtered by centrifugation (1,870g at 37°C). A portion of the filtrate was transferred to an individual scintillation vial. The scintillator Hionic-Fluor (PerkinElmer Life and Analytical Sciences, Waltham, MA) was added to each vial, after which the radioactivity in each sample was counted in a liquid scintillation counter Tricarb-3100TR (PerkinElmer Life and Analytical Sciences). The counting efficiency was corrected using the external standard radiation source method. The unbound fraction of [ 14 C]YM155 in the tumor tissue (i.e., 100% homogenate) was calculated using the following equations: 14 C]YM155 (10, 100, and 1000 ng/ml) was incubated at 37°C for 10 min and then transferred into an ultrafiltration tube (Ultracent-10). After centrifugation at 1,870g for 15 min at 37°C, each filtrate was transferred to a scintillation vial. In addition, the plasma samples not subjected to ultrafiltration were transferred to an individual scintillation vial. Scintillator was added to each vial, and the radioactivity in each sample was counted in a liquid scintillation counter as described above.
In Vitro Blood-to-Plasma Concentration Ratios in Mice. Male BALB/c mouse blood spiked with [ 14 C]YM155 (5, 50, and 500 ng/ml) was incubated at 37°C for 10 min. After incubation, a portion of the blood sample was transferred into a scintillation vial. The hematocrit values were measured by using a portion of the spiked samples (n ϭ 2). The remaining samples were centrifuged at approximately 1500g for 10 min at 37°C to obtain the plasma. A portion of the plasma sample was transferred into a scintillation vial. A liquid scintillator was added to the plasma samples. For blood samples, radioactivity was measured using the combustion method. The samples were placed on a combustion cone and dried in a drying oven at approximately 70°C for at least 8 h. The samples were combusted in a sample oxidizer (A0307 and A30701; PerkinElmer Life and Analytical Sciences) to prepare samples for the determination of the radioactivity. In the sample oxidizer, Carbo-SorbE and Permafluor E ϩ (PerkinElmer Life and Analytical Sciences) were used as carbon dioxide absorbent and liquid scintillator, respectively. In addition, before and after the combustion of the samples, the samples for the determination of recovery (referred to as recovery samples; n ϭ 3) that contained the designated amount of radioactivity were combusted, and the radioactivity was measured. The radioactivity in the reference samples (n ϭ 3) was determined using the direct measurement method. The recovery obtained in the sample oxidizer was calculated as the ratio of radioactivity in the recovery samples to that in the reference samples. The radioactivity was measured with a liquid scintillation counter, the counting efficiency of which was determined using the external standard radiation source method. The blood-to-plasma concentration ratio and blood cell-to-plasma concentration ratio were calculated using the following equations: blood-to-plasma concentration ratio ϭ C blood /C p , and blood cell-to-plasma concentration ratio ϭ (C blood /C p Ϫ (1 Ϫ Ht/100))/(Ht/100), where C p is the concentration of radioactivity in plasma, C blood is the concentration of radioactivity in blood, and Ht is the hematocrit value (percentage).
In Vitro Uptake of [ 14 C]YM155 in Solid Tumor and Lymphoma Cell Lines. Adherent cell lines A375, . A day before the uptake experiments, cells were seeded in 6-well (for cell lines other than PC-3) or 12-well (for PC-3) cell culture plates at the density of 6 ϫ 10 5 cells/well for the 6-well plate or 2.4 ϫ 10 5 cells/well for the 12-well plate and then incubated at 37°C in an atmosphere of 5% CO 2 in humidified air for at least 24 h. For the uptake experiments, cell culture medium was replaced twice with Krebs-Henseleit buffer (11.1 mM d-glucose, 1.17 mM MgSO 4 , 1.18 mM KH 2 PO 4 , 4.69 mM KCl, 143 mM NaCl, 2.54 mM CaCl 2 , and 10 mM HEPES, pH 7.4; either preheated at 37°C or on ice). Uptake was started by replacing the buffer with that containing [ 14 C]YM155 (at a designated concentration, either preheated at 37°C or on ice). At the designated time, uptake was terminated by aspirating the [ 14 C]YM155-containing buffer, followed by the addition of ice-cold buffer. This buffer was immediately aspirated and more ice-cold buffer was added and suctioned off again. The cells were dried by placing the cell culture plate on the hot-plate, and then 1 M NaOH (800 and 500 l for 6-and 12-well plates, respectively) was added to each well to solubilize the cells. After overnight storage, 2 M HCl (400 and 250 l for 6-and 12-well plates, respectively) was added to each well to neutralize the cell lysate. This cell lysate was subjected to radioactivity and protein measurement. Radioactivity was measured by transferring the lysate to a scintillation vial and adding the scintillation cocktail Hionic-Fluor (PerkinElmer Life and Analytical Sciences). The radioactivity of the vials was counted using the liquid scintillation counter Tricarb-3100TR and the external standard radiation source method. The concentrations of cellular protein were measured by the modified Lowry method using a DC protein assay reagent kit (Bio-Rad, Hercules, CA). Time (at 1 M for 1, 3, 5, and 10 min)-and concentration (at 0.05, 0.1, 0.15, 0.2, 0.3, 0.5, 1, 2, 5, 10, 20, and 50 M for 5 min)-dependent uptake of [ 14 C]YM155 was examined using PC-3, Calu-6, NCI-H358, A375, and SK-MEL-5. The effects of various compounds on the uptake of [ 14 C]YM155 were examined using PC-3, Calu-6, and A375. For PC-3 cells, the extracellular pH-, Na ϩ -, and Cl Ϫ -dependent uptake of YM155 was also examined using adequately modified Krebs-Henseleit buffer.
Nonadherent Cell Lines RL and Ramos. Aliquots (120 l) of cell suspension (10.0 or 20.0 ϫ 10 6 viable cells/ml in Krebs-Henseleit buffer, pH 7.4) were transferred to polypropylene tubes. The viability was measured using the trypan blue exclusion method and was not less than 95% throughout the experiments. Before starting the uptake experiments with [
14 C]YM155, the cell suspensions were warmed to 37°C in a water bath or were cooled in iced water for 3 min. The uptake of [ 14 C]YM155 was initiated by adding an equal volume (120 l) of prewarmed or precooled Krebs-Henseleit buffer containing [ 14 C]YM155 (i.e., final 5.0 or 10.0 ϫ 10 6 viable cells/ml), while the samples were still in the 37°C water bath or iced water. At the designated time, uptake was terminated by separating the cells from the solution containing [ 14 C]YM155. For this purpose, an aliquot (200 l) of incubation mixture was transferred to a 400-l polyethylene tube containing 50 l of 2 M NaOH under a 100-l layer of an oil mixture. The sample tube was then centrifuged at 10,000g for approximately 10 s. During this process, the cells passed through the oil layer into an alkaline solution, whereas the solution containing 
, where P dif is uptake clearance by passive diffusion and/or nonspecific binding to the cell surface. The half-maximal inhibitory concentration (IC 50 ) values were calculated from the calibration curve, based on the two points for the logarithm of concentrations versus uptake (percentage of control) at approximately 50% inhibition.
Results
In Vivo Distribution of [
14 C]YM155 in PC-3-Xenografted Nude Mice Using Whole Body Radioluminography. The radioluminogram showing distribution of radioactivity 72 h after [
14 C]YM155 infusion is shown in Fig. 2 . The highest levels of radioactivity were detected in the contents of the large (386.71 PSL/mm 2 ) and small (28.20 PSL/mm 2 ) intestines and were 348 and 25 times higher than that in the blood (1.11 PSL/mm 2 ), respectively. Radioactivity in the tumor, kidney, and liver (16.36, 9.63, and 4.20 PSL/mm 2 , respec-
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at ASPET Journals on January 6, 2018 dmd.aspetjournals.org Downloaded from tively) were also considerably higher (15, 9, and 4 times higher, respectively) than in the blood. Traces of radioactivity were detected in the submaxillary glands and skin. The high radioactivity in the intestinal contents after subcutaneous administration of [ 14 C]YM155 suggested that the radioactivity absorbed subcutaneously into the systemic circulation, i.e., blood, was excreted into the intestinal tract via bile after the distribution into the liver. Apart from the gastrointestinal contents, the highest radioactivity was observed in the tumor tissues. In the section of slice containing tumor tissue ( Fig. 2A) , the radioactivity was only detected in the tumor; it was not detected in the rest of the section (skin, bone, and muscles).
In Vitro Binding of [ 14 C]YM155 to the Tumor Tissue Homogenate. The in vitro unbound fraction of YM155 (%) in PC-3 tumor tissue ranged from 40.47 to 50.05%. The unbound fraction was independent of homogenate concentration (15 and 30%), YM155 concentration (100 and 1000 ng/ml), and incubation time (10 and 60 min).
In Vitro Unbound Fraction in Plasma and Blood-to-Plasma Concentration Ratio of [
14 C]YM155 in Mice. The in vitro unbound fraction of YM155 in mouse plasma ranged from 77.62 to 81.40% at the concentration range tested (Table 1) , whereas plasma protein binding of YM155 was low. The in vitro blood-to-plasma concentration ratio and the blood cell-to-plasma concentration ratio were also low, indicating that very little YM155 was distributed into the blood cells (Table 1) . Very low distribution into the blood cells and no concentration-dependent saturation suggested the lack of uptake transporter in blood cells. (Fig. 4) Subsequently, the concentration-dependent inhibitory effects of cationic transporter substrates/inhibitors tributylmethylammonium (TBMEA), MPP, cimetidine, prazosin, corticosterone quinidine, verapamil, amantadine, procainamide, and NMN on the 5-min uptake of [ 14 C]YM155 (0.1 M) into PC-3 were examined (figure not shown). The IC 50 values obtained are listed in Table 3 . The IC 50 values of compounds inhibiting the human OCT1-, OCT2-, OCT3 (SLC22A3)-, OCTN1-, OCTN2-, and OCT6-mediated transport of prototypical substrates (instead of YM155) (Koepsell et al., 2003 (Koepsell et al., , 2007 obtained from the literature are also listed in Table 3 . Each inhibitor shows different affinity to OCT1, OCT2, OCT3, OCTN1, OCTN2, and/or OCT6. The comparison between IC 50 values for the YM155 uptake into PC-3 cells and those for each transporter in literature would be informative to identify the exact transporter involved in the uptake of YM155 into cancer cells. It was assumed that, for example, if YM155 had been transported by OCT1 in PC-3 cells, IC 50 values for the uptake of YM155 into PC-3 would have been consistent with those for 
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at ASPET Journals on January 6, 2018 dmd.aspetjournals.org results suggested the voltage-dependent transport of YM155 into the PC-3 cells. When the Cl Ϫ in the buffer was replaced by gluconate, a slight, but not marked, decrease in the uptake was observed (data not shown). The pH and Na ϩ dependencies (Fig. 7) were similar to those of organic cation transporters (Gründemann et al., 1994; Kakehi et al., 2002) . These results seem reasonable because YM155 has a cationic moiety in its structure (Fig. 1) .
Discussion
YM155 is a new first-in-class molecular entity that suppresses survivin and shows potent antitumor activity in various types of cancer cells, including PC-3 cells, both in vitro and/or in vivo (Nakahara et al., 2007) . YM155 showed high distribution into its pharmacologically effective site, tumor tissue, after administration to nude mice bearing PC-3 cells. This preferential distribution property is considered to result in antitumor activity without the induction of severe systemic toxicity in vivo (Nakahara et al., 2007) . The in vitro 50% cell growth inhibition concentration for YM155 was 8.2 nM in PC-3 cells after treatment with YM155 for 48 h (Nakahara et al., 2007) . At the pharmacologically effective dose, 3 mg/kg in vivo, the plasma concentration of YM155 was approximately 20 ng/ml (55 nM) at steady state during subcutaneous infusion of YM155 to nude mice Table 2 .
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at ASPET Journals on January 6, 2018 dmd.aspetjournals.org bearing a PC-3 tumor (Nakahara et al., 2007) . Given that the unbound fraction of YM155 in mouse plasma is approximately 80%, the unbound plasma concentration is estimated to be 44 nM. Therefore, the pharmacologically effective concentrations in vitro and in vivo are comparable. In addition, the metabolism of YM155 was very low (Sohda et al., 2007) . Therefore, YM155 itself (rather than its metabolites, if any) could be considered to be the main pharmacologically active component, and the pharmacological target organ may be the tumor itself both in vivo and in vitro. The radioluminogram showed high levels of radioactivity in the tumor, kidney, and liver as well as the excreta (large intestinal contents and small intestinal contents) (Fig. 2) . Only a trace of radioactivity was detected in the submaxillary gland and skin. These results suggested that, compared with most other organs, the greatest proportion of [ 14 C]YM155 is distributed to the tumor, which is the target organ (the tumor-to-blood radioactivity ratio was 14.7). In general, high tissue distribution of a drug results from a high rate of binding of the drug to the cell surface and intracellular component, and/or carrier-mediated uptake into the cells. Taking the in vitro unbound fraction of YM155 in tumor tissue and plasma as well as the blood-to-plasma radioactivity ratio into account, the tumor-to-plasma concentration ratio based on the unbound concentration was estimated to be 4.3 to 5.6. For the tumor-to-plasma ratio of the total YM155 concentration (16.7-24.6) (Nakahara et al., 2007) , the value was recalculated to be 9.5-13.9, based on the unbound concentration (unpublished data). This high ratio suggested that tumor-tissue binding alone could not fully explain the high distribution of YM155 in the tumor; therefore, carrier-mediated uptake of YM155 into the cancer cells was postulated. Subsequently, a detailed characterization of the uptake of [ 14 C]YM155 into solid tumor and lymphoma cells was performed in vitro. The similarity of the results among the cell lines tested indicates similar uptake mechanism for the uptake of YM155 into solid tumor and lymphoma cells. The temperature-and saturable concentrationdependent uptake of [ 14 C]YM155 into solid tumor and lymphoma cell lines indicated the involvement of transporter(s). The K m values were similar among the cell lines tested, suggesting similar uptake mechanism for the uptake of YM155 into solid tumor and lymphoma cells. It has been reported that water-soluble anticancer drugs, nucleoside analogs, and antifolates are taken up by drug transporters on the plasma membrane of the cancer cells (Huang and Sadée, 2006) . Transporters of endogenous or nutrient substances such as folate, nucleic acid, and sugar have been studied extensively (Huang and a Values are cited from the review articles by Koepsell et al. (2003 Koepsell et al. ( , 2007 . b Based on the results in Fig. 5 . c K m values.
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Nonradiolabeled YM155 (10 (Koepsell et al., 2007) . It has recently been reported that OCTs are expressed in cancer cells and are associated with drug accumulation and chemosensitivity, e.g., OCT1 for imatinib (Thomas et al., 2004; Wang et al., 2008) , OCT1/OCT2 for oxaliplatin (Yonezawa et al., 2006; Zhang et al., 2006) , and OCT6 for doxorubicin (Okabe et al., 2005) . In patients with chronic myeloid leukemia, the expression of OCT1 is a powerful predictor of a complete cytogenic response (Wang et al., 2008) . Based on the expression of OCT1 and OCT2 in the colon cancer tissue samples as well as the OCT-dependent activity of oxaliplatin in the cell lines, it is reasonable to speculate that these transporters are important determinants of oxaliplatin activity in colorectal cancer (in contrast, OCT1 and OCT2 are relatively unimportant for mediating the uptake and cytotoxicity of cisplatin and carboplatin, which are also transported by these two transporters) (Zhang et al., 2006) . YM155 is also a water-soluble anti-cancer drug with a cationic moiety. Furthermore, it has been shown that YM155 is transported by human OCT1 . Initially, it had been considered that OCT1 would have been possibly involved in the uptake of YM155 into cancer cells; however, the present study using various OCT inhibitors did not suggest the major involvement of OCT1 as well as OCT2 or OCT3 (Table 3) . Moreover, the K m value (approximately 20 M; Minematsu et al., 2007) for OCT1-mediated transport of YM155, which was very different from those for uptake of YM155 into the cancer cells (0.189 -0.367 M), also did not suggest the involvement of OCT1. For the other organic cation transporters, carnitine, which is an inhibitor of OCTN1, OCTN2, and OCT6, did not inhibit the uptake of YM155 ( Fig. 5; Table 3 ). As well as the involvement of OCTs mentioned above, those of other cation transporters, organic anion transporters that also transport organic cations, endogenous cationic substrate transporters, and others should be investigated in future studies.
For the distribution of YM155 into normal tissues instead of tumor, the high levels of radioactivity detected in the contents of the large and small intestines (Fig. 2) were well explained by the biliary excretion of radioactivity after high distribution into the liver. Biliary excretion is a major excretion route of YM155 in rats and dogs (unpublished data). Because YM155 is transported by human OCT1 and because OCT1 is highly expressed in mouse liver (Mooslehner and Allen, 1999; Alnouti et al., 2006) , it is likely YM155 is taken up into the hepatocytes by OCT1 in mice. Because OCT1 is also located on the basolateral membrane of enterocytes in mice (Koepsell et al., 2007) , the distribution of YM155 into these enterocytes from the blood is also probable. In Oct1-knockout mice, the concentrations of TEA in the liver and small intestine decreased, as did the biliary excretion of TEA (Koepsell et al., 2007) . It is likely that more than one transporter is involved in the pharmacokinetics of YM155. OCT1 is involved in the distribution of YM155 into the liver, another (or more) is involved in uptake into cancer cells, and still others for uptake into other tissues.
In conclusion, YM155 showed high distribution to tumor tissues after continuous administration to nude mice bearing PC-3 tumors. The in vitro experiments suggested that YM155 was taken up into various cancer cells in a carrier-mediated manner. This process occurred with similar affinity among the cancer cell lines tested: prostate cancer, lung cancer, melanoma, and non-Hodgkin's lymphoma. A drug transporter(s) for organic cations may contribute to this process. Further investigation is needed to identify the transporter for possible optimization of cancer chemotherapy using YM155. 
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